Eli Lilly Vs. Pfizer in 2027: One Is a Much Better Place to Park Your Pharmaceutical Capital Next Year
Lilly and Pfizer both reported recent quarters that turned heads for opposite reasons, and heading into 2027 only one of them deserves your pharmaceutical capital. The answer depends on a trade-off most investors get wrong.
This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.
Eli Lilly (NYSE:LLY | LLY Price Prediction) and Pfizer (NYSE:PFE) just gave investors two very different pharma stories. Lilly’s latest quarter showcased runaway incretin demand and a raised outlook. Pfizer’s showed a diversified book slowly stabilizing after COVID, with a fresh obesity bet stapled on. Heading into 2027, the question is whether uncapped growth or defensive transformation deserves your capital.
Mounjaro Runs the Table, Pfizer Steadies the Base
Lilly’s Q2 2026 earnings report was category-defining. Revenue hit $22.97B, up 47.7% year over year, driven by Mounjaro at $9.94B (+91%) and Zepbound at $4.93B (+46%). International Mounjaro sales jumped 172% following China NRDL listing, a real signal that GLP-1 demand is global. CEO David Ricks called Lilly’s future “never been brighter” after 150 years, and management raised FY2026 revenue guidance to $85.0B to $87.0B.
Pfizer’s Q1 2026 was quieter but more encouraging than skeptics expected. Revenue reached $14.45B, up 5.4%, with adjusted EPS of $0.75. Growth came from newer assets: Padcev at $591M (+39%), Nurtec at $353M (+42%), and oncology biosimilars at $409M (+55%). COVID drag continued, with Comirnaty down 59% and Paxlovid down 62%. Albert Bourla told investors Pfizer will “successfully navigate this defining period”, leaning on oncology and a late obesity push.
Uncapped Growth Versus Defensive Value
| Lens | Lilly | Pfizer |
| Core Bet | Incretin dominance plus retatrutide BLA in Q1 2027 | $7B Metsera obesity entry, oncology depth |
| 2027 EPS Estimate | $47.34 avg, 27 analysts | $2.8970 avg, 25 analysts |
| Forward P/E | 24x | 9x |
| Dividend Yield | 0.56% | 6.22% |
| Key Vulnerability | US realized prices down ~9%, capacity limits | ~$1.5B LOE headwind, obesity late |
Lilly is compounding off scarcity. Pfizer is engineering a floor with yield, biosimilars, and pipeline reinvestment. Both are legitimate strategies. They just answer different questions.
2027 Catalysts Worth Marking on the Calendar
For Lilly, the swing factor is retatrutide’s BLA filing in Q1 2027 across obesity, sleep apnea, and knee osteoarthritis pain. Analyst momentum reflects it: 19 upward EPS revisions versus 4 downward in the past 30 days for FY2027. I will watch whether new Indiana manufacturing capacity closes the persistent supply gap.
For Pfizer, the tests are Metsera’s 10 pivotal starts in 2026, the Vyndamax exclusivity extended to June 2031, and Most-Favored-Nation pricing outcomes. You should also track whether oncology can keep offsetting primary-care softness.
Why I Would Park 2027 Capital in Lilly, With One Caveat
Personally, I lean Lilly for 2027. The incretin franchise is running ~$14.87B in a single quarter, retatrutide is queued, and analysts have marched EPS estimates higher. Shares are up 56.02% over the past year, so you are not buying it cheap. If you want a 6.22% yield and a lower entry multiple while a turnaround plays out, Pfizer fits. For anyone building a 2027 growth allocation, Lilly is the better place to park pharmaceutical capital, provided you can stomach the premium.
Contact [email protected] for any questions or corrections.
Alex Sirois is a financial writer with experience spanning both retail and institutional investing. He has written for InvestorPlace and held roles at BNY Mellon and Bernstein, giving him a perspective that bridges Main Street portfolios and Wall Street analysis.
Alex holds an MBA from George Washington University and has built his career across multiple industries, including e-commerce, education, and translation — a breadth of experience that informs how he breaks down complex financial topics for everyday investors. His writing is conversational, actionable, and grounded in long-term, buy-and-hold investing principles.
At 247 Wall St., Alex focuses on delivering analysis that is both accessible and useful, with a clear emphasis on helping readers make more informed decisions with their money.
